Novo Nordisk taps into Canadian biotech’s cell therapies for diabetes and obesity in deal worth up to $2.6B
As Vertex moves its diabetes cell therapies through early-stage clinical testing, longtime diabetes player Novo Nordisk is now looking to do the same via a partnership with a private Canadian biotech.
The Danish drugmaker will dole out $75 million to Aspect Biosystems for four cell therapy candidates across diabetes and obesity. Each candidate comes with $650 million in potential milestone payments, adding up to $2.6 billion in biobucks. Tiered royalties are also part of the agreement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.